ArticleFish physiology and biochemistry2026
Assessment on the effects of different lipid sources in juvenile largemouth bass (Micropterus salmoides) diets.
Article in Fish physiology and biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
To evaluate the effects of substituting soybean oil (SO) with soy lecithin (SL) and specialty lipid (CL) on the growth, body composition, and glucose-lipid metabolism of juvenile largemouth bass (Micropterus salmoides). The CL is a composite lipid source formulated by mixing coconut oil, linseed oil, soy lecithin oil, and palm oil in a ratio of 2:2:3:3, with the addition of antioxidants and emulsifiers as fillers. A total of six experimental groups were established: an iso-nitrogenous and iso-lipidic soybean oil (SO) (control group), a 1% soy lecithin supplementation group (1% SL), a 2% soy lecithin supplementation group (2% SL), a 2.5% specialty lipid supplementation group (2.5% CL), a 5% specialty lipid supplementation group (5% CL), and a 7.5% specialty lipid supplementation group (7.5% CL). After a 10-week feeding trial (initial body weight: 12.64 ± 0.02 g), the results showed that final body weight (FBW), weight gain rate (WGR), and specific growth rate (SGR) in the 2.5% CL and 5% CL groups were significantly higher than those in the SO group. The 5% CL group exhibited the lowest feed conversion ratio (FCR) numerically, though no significant differences were observed among groups. Whole-body crude lipid content was significantly reduced in the 7.5% CL. Compared to other groups, the 5% CL and 7.5% CL showed significantly increased levels of saturated fatty acid (SFA), docosahexaenoic acid (DHA), and n-3/n-6 polyunsaturated fatty acid (PUFA), while PUFA levels markedly decreased. Compared to the control, the 7.5% CL showed significant decreases in plasma serum albumin (ALB), total protein (TP), total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), and low-density lipoprotein (LDL). Regarding lipid metabolism gene expression, the 5% CL exhibited a significantly lower expression level of the peroxisome proliferator-activated receptor-γ (pparγ) in contrast to SO. The expression levels of peroxisome proliferators-activated receptor-α (pparα) were significantly upregulated in the 5% CL and 7.5% CL compared to other groups. Furthermore, the carnitine palmitoyltransferase (cpt1) expression level in the 5% CL was significantly higher than in all other groups. In conclusion, CL enhanced growth performance, effectively reduced whole-body lipid deposition, improved fatty acid composition, and promoted lipid metabolism in juvenile largemouth bass, without adversely affecting liver function. Based on the comprehensive results, the recommended optimal inclusion level for specialty lipid was 5%.
Indexed as
Identifiers
42101526What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.